HBM contact: Dr Ivo Staijen, Dr Chandra P. Leo
Company status: public
C4 Therapeutics is developing small-molecule
drugs that selectively destroy disease-causing proteins via degradation using
the innate machinery of the cell. This targeted protein degradation
approach offers advantages over traditional drugs, including the potential to
treat a wider range of diseases, reduce drug resistance, achieve higher
potency, and decrease side effects through greater selectivity.